HUPHAR names cariprazine ʼ2019 Medicine of the Yearʼ
The Hungarian Society for Experimental and Clinical Pharmacology (HUPHAR) has named Gedeon Richterʼs antipsychotic cariprazine "2019 Medicine of the Year", according to a report by state news wire MTI.
At a ceremony late Thursday, HUPHAR chairman Péter Ferdinandy said cariprazine is the first "genuine" Hungarian drug, discovered and developed by Richter researchers, in many years. The drug has gained a foothold on global markets and has a "great future" ahead of it, he added.
Richter chairman Erik Bogsch noted that cariprazine, the product of 18 years of research, is the first Hungarian-developed original preparation to be introduced on the United States market.
Cariprazine, marketed under the brand names Vraylar and Reagila, was Richterʼs second best-selling drug last year, generating a turnover of HUF 57.7 billion.
Hungary Gasoline Prices 3% Over Regional Avg
Hungary to Address Future of Cohesion Policy During EU Presi...
Cordia’s Marina City Project Begins
Budapest Airport Wins 'Best Airport in Eastern Europe' for 1...
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Producing journalism that is worthy of the name is a costly business. For 27 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
